Silver Book Fact

Around $35 billion cost to society from antibiotic resistant infections

The societal costs of antibiotic resistant infections are around $35 billion each year- this includes the cost of lost wages and premature deaths.

Roberts, Rebecca R., Bala Hota, Ibrar Ahmad, R. Douglas Scott, Susan D. Foster, Fauzia Abbasi, Shari Schabowski, Linda M. Kampe, Ginerva G. Ciavarella, Mark Supino, Jeremy Naples, Ralph Cordell, Stuart B. Levy, and Robert A. Weinstein. Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implicatons for antibiotic stewardship. Clin Infect Dis. 2009; 49(8): 1175-84. http://cid.oxfordjournals.org/content/49/8/1175.full

Reference

Title
Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implicatons for antibiotic stewardship
Publication
Clin Infect Dis
Publication Date
2009
Authors
Roberts, Rebecca R., Bala Hota, Ibrar Ahmad, R. Douglas Scott, Susan D. Foster, Fauzia Abbasi, Shari Schabowski, Linda M. Kampe, Ginerva G. Ciavarella, Mark Supino, Jeremy Naples, Ralph Cordell, Stuart B. Levy, and Robert A. Weinstein
Volume & Issue
Volume 49, Issue 8
Pages
1175-84
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Enormous annual direct cost of HAIs to hospitals
    The annual direct cost of healthcare-associated infections to U.S. hospitals ranges from $28.4 billion to $45 billion.  
  • Hospital-acquired pneumonia leading cause of HAI
    Hospital-acquired pneumonia (HAP) is the 2nd most frequent cause of hospital-acquired infection, numbering around 300,000 cases each year.  
  • Significant increase of penicillin-resistant Streptococcus penumoniae
    High-level penicillin-resistant Steptococcus pneumoniae increased 1,000-fold over 17 years.  
  • 1 in 4 inpatient pneumonia hospitalizations due to HAIs
    In one study, one in four inpatient pneumonia hospitalizations were from health-care-associated pneumonia.  
  • Drug-resistant MRSA expensive to treat
    As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.